289 related articles for article (PubMed ID: 28228084)
1. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
Sato-Dahlman M; Yamamoto M
Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
3. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
[TBL] [Abstract][Full Text] [Related]
4. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.
José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C
J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?
Yoon AR; Hong J; Jung BK; Ahn HM; Zhang S; Yun CO
Cancer Lett; 2023 Nov; 579():216456. PubMed ID: 37940067
[TBL] [Abstract][Full Text] [Related]
6. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
7. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
8. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
[TBL] [Abstract][Full Text] [Related]
9. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
10. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K
J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in genetic modification of adenovirus vectors for cancer treatment.
Yamamoto Y; Nagasato M; Yoshida T; Aoki K
Cancer Sci; 2017 May; 108(5):831-837. PubMed ID: 28266780
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.
Choi IK; Yun CO
Cancer Gene Ther; 2013 Feb; 20(2):70-6. PubMed ID: 23306610
[TBL] [Abstract][Full Text] [Related]
14. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
16. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.
Li Y; Hong J; Oh JE; Yoon AR; Yun CO
Int J Cancer; 2018 Jan; 142(2):392-413. PubMed ID: 28929492
[TBL] [Abstract][Full Text] [Related]
17. Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells.
Bofill-De Ros X; Villanueva E; Fillat C
Oncotarget; 2015 Mar; 6(8):6179-90. PubMed ID: 25714032
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.
Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO
J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
